Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia

P. Wright, M. Birkett, S. R. David, K. Meehan, I. Ferchland, K. J. Alaka, J. C. Saunders, J. Krueger, P. Bradley, L. San, M. Bernardo, M. Reinstein, A. Breier

Research output: Contribution to journalArticlepeer-review

241 Scopus citations

Abstract

Objective: The authors evaluated the comparative efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular placebo for the treatment of acute agitation in schizophrenia. Method: Hospitalized patients with schizophrenia received one to three injections of intramuscular olanzapine, 10 mg, intramuscular haloperidol, 7.5 mg, or intramuscular placebo over a 24-hour period. Agitation was measured with the excited component of the Positive and Negative Syndrome Scale and two additional scales. Results: According to scores on the excited component of the Positive and Negative Syndrome Scale, both intramuscular olanzapine and intramuscular haloperidol reduced agitation significantly more than intramuscular placebo 2 and 24 hours following the first injection. Intramuscular olanzapine reduced agitation significantly more than intramuscular haloperidol 15, 30, and 45 minutes following the first injection. No patients treated with intramuscular olanzapine experienced acute dystonia, compared with 7% of those who were treated with intramuscular haloperidol. No significant QTc interval changes were observed in any patients. Conclusions: Intramuscular olanzapine represents a rapid, effective, and safe treatment for acute agitation in schizophrenia.

Original languageEnglish (US)
Pages (from-to)1149-1151
Number of pages3
JournalAmerican Journal of Psychiatry
Volume158
Issue number7
DOIs
StatePublished - 2001

ASJC Scopus subject areas

  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia'. Together they form a unique fingerprint.

Cite this